Exclusive: Malaysia’s A-Bio invests $1.8m in pathology service provider Clinipath

HiFiBiO Therapeutics
A biological testing process underway at a personal products lab. Photo: Bloomberg

A-Bio, a strategic investment firm established by the Malaysian government, has invested RM7 million ($1.8 million) in Clinipath Malaysia, one of the country’s leading pathology service providers.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe